Last 7 days
1.7%
Last 30 days
-8.9%
Last 90 days
-4.4%
Trailing 12 Months
-4.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HCA | 73.0B | 60.9B | -4.91% | 25.24% | 12.73 | 1.2 | 1.94% | -15.77% |
LH | 20.7B | 14.8B | -2.77% | -13.32% | 16.22 | 1.39 | -6.96% | -52.35% |
DGX | 15.0B | 9.6B | -8.90% | -4.59% | 18.89 | 1.56 | -10.08% | -57.84% |
MID-CAP | ||||||||
UHS | 9.9B | 13.6B | -10.37% | 3.84% | 14.64 | 0.74 | 5.04% | -26.87% |
EHC | 6.1B | 4.4B | -5.92% | 18.26% | 22.47 | 1.4 | 8.15% | -30.89% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
ENSG | 5.0B | 3.2B | -11.17% | 9.89% | 21.14 | 1.55 | 17.88% | 19.62% |
AMN | 3.9B | 4.8B | 11.84% | 2.65% | 10.12 | 0.8 | 3.57% | -4.88% |
GH | 2.9B | 482.2M | 34.10% | -27.10% | -4.41 | 5.98 | 23.29% | -70.12% |
AMED | 2.5B | 2.2B | 0.86% | -34.14% | 22.43 | 1.13 | 0.55% | -41.23% |
SMALL-CAP | ||||||||
RDNT | 1.7B | 1.5B | 6.01% | 44.82% | -126.07 | 1.14 | 10.24% | -173.11% |
BKD | 645.6M | 2.9B | -18.53% | -39.08% | -3.53 | 0.22 | 7.97% | -101.02% |
ENZ | 111.6M | 81.1M | -7.29% | 3.62% | -3.17 | 1.38 | -31.36% | -11847.33% |
XGN | 52.2M | 46.4M | 22.05% | -38.86% | -1.16 | 1.12 | -3.55% | -44.93% |
PMD | 28.0M | 25.2M | -8.89% | -21.14% | -25.78 | 1.11 | 1.33% | -63.01% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | -2.8% | 9,603 | 9,883 | 10,294 | 10,582 | 10,679 |
Cost Of Revenue | -1.3% | 6,364 | 6,450 | 6,593 | 6,645 | 6,599 |
S&GA Expenses | 0.7% | 1,888 | 1,874 | 1,775 | 1,738 | 1,745 |
Costs and Expenses | -0.9% | 8,383 | 8,455 | 8,465 | 8,493 | 8,445 |
EBITDA | -19.8% | 1,534 | 1,912 | 2,203 | 2,688 | - |
EBITDA Margin | -16.4% | 0.16* | 0.19* | 0.21* | 0.25* | - |
Earnings Before Taxes | -14.2% | 1,060 | 1,235 | 1,628 | 1,931 | 2,425 |
EBT Margin | -21.0% | 0.12* | 0.16* | 0.18* | 0.23* | - |
Interest Expenses | 1.4% | -136 | -138 | -143 | -148 | -150 |
Net Income | -16.2% | 793 | 946 | 1,235 | 1,484 | 1,881 |
Net Income Margin | -20.2% | 0.10* | 0.12* | 0.14* | 0.18* | - |
Free Cahsflow | -10.2% | 1,314 | 1,464 | 1,552 | 1,602 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -0.3% | 12,794 | 12,837 | 13,223 | 13,312 | 13,442 |
Current Assets | -4.4% | 1,814 | 1,898 | 2,334 | 2,426 | 2,475 |
Cash Equivalents | -44.4% | 175 | 315 | 700 | 790 | 712 |
Inventory | -1.0% | 190 | 192 | 183 | 187 | 197 |
Net PPE | 1.6% | 1,795 | 1,766 | 1,707 | 1,664 | 1,668 |
Goodwill | 0.3% | 7,241 | 7,220 | 7,190 | 7,195 | 7,197 |
Current Liabilities | -12.6% | 1,355 | 1,551 | 1,602 | 1,577 | 1,700 |
Long Term Debt | -0.1% | 3,975 | 3,978 | 3,980 | 3,983 | 3,985 |
LT Debt, Current | 0% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Shareholder's Equity | 2.7% | 6,050 | 5,893 | 6,235 | 6,450 | 6,415 |
Retained Earnings | 1.5% | 8,412 | 8,290 | 8,263 | 8,083 | 7,926 |
Additional Paid-In Capital | -1.3% | 2,266 | 2,295 | 2,272 | 2,250 | 2,226 |
Shares Outstanding | -3.4% | 112 | 116 | 117 | 119 | - |
Minority Interest | 2.7% | 38.00 | 37.00 | 37.00 | 39.00 | 38.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -22.5% | 1,332 | 1,718 | 1,865 | 1,924 | 1,982 |
Share Based Compensation | 7.8% | 83.00 | 77.00 | 74.00 | 77.00 | 79.00 |
Cashflow From Investing | 2.0% | -532 | -543 | -596 | -574 | -55.00 |
Cashflow From Financing | 22.8% | -1,337 | -1,732 | -1,556 | -1,120 | -2,445 |
Dividend Payments | 0% | 305 | 305 | 307 | 305 | 308 |
Buy Backs | -26.5% | 1,035 | 1,408 | 1,236 | 862 | 2,162 |
58.5%
19.2%
0%
Y-axis is the maximum loss one would have experienced if Quest Diagnostics was unfortunately bought at previous high price.
10.0%
10.2%
6.7%
7.6%
FIve years rolling returns for Quest Diagnostics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Brookfield Corp /ON/ | added | 31.47 | 1,068,140 | 6,721,570 | 0.03% |
2023-05-23 | MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID | unchanged | - | -51,612 | 488,106 | 0.04% |
2023-05-23 | Front Row Advisors LLC | unchanged | - | -2,000 | 19,000 | 0.01% |
2023-05-23 | Toroso Investments, LLC | added | 21.96 | 88,000 | 954,000 | 0.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -11.54 | -29,214,500 | 116,864,000 | 0.04% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -22.68 | -126,746 | 294,703 | -% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 1,682,000 | 0.07% |
2023-05-22 | Raleigh Capital Management Inc. | added | 23.72 | 2,848 | 27,282 | 0.01% |
2023-05-18 | JPMORGAN CHASE & CO | added | 379 | 158,778,000 | 206,310,000 | 0.03% |
2023-05-18 | SkyView Investment Advisors, LLC | new | - | - | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 12.27% | 13,973,339 | SC 13G/A | |
Feb 07, 2023 | state street corp | 5.16% | 5,879,980 | SC 13G/A | |
Jan 23, 2023 | blackrock inc. | 10.9% | 12,391,327 | SC 13G/A | |
Apr 08, 2022 | blackrock inc. | 10.7% | 12,807,624 | SC 13G/A | |
Feb 10, 2022 | state street corp | 5.11% | 6,268,789 | SC 13G | |
Feb 07, 2022 | blackrock inc. | 9.5% | 11,636,382 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 10.64% | 14,337,685 | SC 13G/A | |
Feb 01, 2021 | blackrock inc. | 8.5% | 11,464,215 | SC 13G/A | |
Feb 13, 2020 | macquarie group ltd | 0.20% | 271,969 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 11.42% | 15,394,930 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 78.11 -41.61% | 101.69 -23.98% | 129.15 -3.45% | 225.86 68.84% | 311.56 132.91% |
Current Inflation | 72.87 -45.53% | 93.46 -30.13% | 116.75 -12.72% | 198.93 48.71% | 271.32 102.83% |
Very High Inflation | 66.25 -50.47% | 83.29 -37.74% | 101.79 -23.91% | 167.42 25.16% | 224.78 68.03% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 19, 2023 | 3 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-17 | MAIN TIMOTHY L | acquired | - | - | 1,369 | - |
2023-05-17 | Gregg Vicky B | acquired | - | - | 1,369 | - |
2023-05-17 | Doi Tracey | acquired | - | - | 1,369 | - |
2023-05-17 | RING TIMOTHY M | acquired | - | - | 1,369 | - |
2023-05-17 | Lassiter Wright III | acquired | - | - | 1,369 | - |
2023-05-17 | MORRISON DENISE M | acquired | - | - | 1,369 | - |
2023-05-17 | Diaz Luis | acquired | - | - | 1,369 | - |
2023-05-17 | WILENSKY GAIL R | acquired | - | - | 1,369 | - |
2023-05-17 | PFEIFFER GARY M | acquired | - | - | 1,369 | - |
2023-04-24 | KUPPUSAMY KARTHIK | acquired | 3,576 | 143 | 25.00 | svp, clinical solutions |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Net revenues | $ 2,331 | $ 2,611 |
Operating costs and expenses and other operating income: | ||
Cost of services | 1,560 | 1,646 |
Selling, general and administrative | 439 | 425 |
Amortization of intangible assets | 26 | 27 |
Other operating expense, net | 1 | 0 |
Total operating costs and expenses, net | 2,026 | 2,098 |
Operating income | 305 | 513 |
Other income (expense): | ||
Interest expense, net | (35) | (37) |
Other income (expense), net | 7 | (24) |
Total non-operating expense, net | (28) | (61) |
Income before income taxes and equity in earnings of equity method investees | 277 | 452 |
Income tax expense | (65) | (110) |
Equity in earnings of equity method investees, net of taxes | 5 | 31 |
Net income | 217 | 373 |
Less: Net income attributable to noncontrolling interests | 15 | 18 |
Net income attributable to Quest Diagnostics | $ 202 | $ 355 |
Earnings per share attributable to Quest Diagnostics’ common stockholders: | ||
Basic (in dollars per share) | $ 1.80 | $ 2.97 |
Diluted (in dollars per share) | $ 1.78 | $ 2.92 |
Weighted average common shares outstanding: | ||
Basic (in Shares) | 112 | 119 |
Diluted (in Shares) | 113 | 121 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Assets | ||
Cash and cash equivalents | $ 175 | $ 315 |
Accounts receivable, net of allowance for credit losses of $30 as of both March 31, 2023 and December 31, 2022 | 1,254 | 1,195 |
Inventories | 190 | 192 |
Prepaid expenses and other current assets | 195 | 196 |
Total current assets | 1,814 | 1,898 |
Property, plant and equipment, net | 1,795 | 1,766 |
Operating lease right-of-use assets | 589 | 585 |
Goodwill | 7,241 | 7,220 |
Intangible assets, net | 1,077 | 1,092 |
Investments in equity method investees | 128 | 132 |
Other assets | 150 | 144 |
Total assets | 12,794 | 12,837 |
Liabilities and Stockholders' Equity | ||
Accounts payable and accrued expenses | 1,198 | 1,396 |
Current portion of long-term debt | 2 | 2 |
Current portion of long-term operating lease liabilities | 155 | 153 |
Total current liabilities | 1,355 | 1,551 |
Long-term debt | 3,975 | 3,978 |
Long-term operating lease liabilities | 490 | 489 |
Other liabilities | 809 | 812 |
Commitments and contingencies | ||
Redeemable noncontrolling interest | 77 | 77 |
Quest Diagnostics stockholders’ equity: | ||
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2023 and December 31, 2022; 162 shares issued as of both March 31, 2023 and December 31, 2022 | 2 | 2 |
Additional paid-in capital | 2,266 | 2,295 |
Retained earnings | 8,412 | 8,290 |
Accumulated other comprehensive loss | (18) | (21) |
Treasury stock, at cost; 50 and 51 shares as of March 31, 2023 and December 31, 2022, respectively | (4,612) | (4,673) |
Total Quest Diagnostics stockholders' equity | 6,050 | 5,893 |
Noncontrolling interests | 38 | 37 |
Total stockholders' equity | 6,088 | 5,930 |
Total liabilities and stockholders' equity | $ 12,794 | $ 12,837 |